Aripiprazole Tablet
Product Images NDC 16714-142

16 FDA label images from Northstar Rxllc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 16714-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazolestructure (Aripiprazolestructure)

Aripiprazolestructure (Aripiprazolestructure)
Chemical structure of Aripiprazole, showing its molecular composition with chlorine-substituted aromatic rings, piperazine, and other functional groups characteristic of this active ingredient.*
FDA Label Image

Aripiprazolefigure1 (Aripiprazolefigure1)

Aripiprazolefigure1 (Aripiprazolefigure1)
Pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals for area under the curve (AUC) and peak concentration (Cmax) when co-administered with various inhibitors, inducers, and other drugs. The chart compares changes relative to reference values without interacting drugs, including CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other medications such as valproate, lithium, and lorazepam.*
FDA Label Image

Aripiprazolefigure2 (Aripiprazolefigure2)

Aripiprazolefigure2 (Aripiprazolefigure2)
A horizontal bar chart showing the effect of various drugs on the pharmacokinetics (PK) of Aripiprazole, specifically dehydro-aripiprazole fold change and 90% confidence intervals. The chart compares AUC and Cmax values relative to a reference without interacting drugs for ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*
FDA Label Image

Aripiprazolefigure3 (Aripiprazolefigure3)

Aripiprazolefigure3 (Aripiprazolefigure3)
A horizontal bar plot illustrating the effect of Aripiprazole on the pharmacokinetics (PK) of various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The graph shows fold change and 90% confidence intervals comparing drug exposure (AUC, Cmax, INR) relative to references without Aripiprazole, with values displayed on the x-axis from 0.5 to 3.0.*
FDA Label Image

Aripiprazolefigure4 (Aripiprazolefigure4)

Aripiprazolefigure4 (Aripiprazolefigure4)
A pharmacokinetic chart titled "Aripiprazole Fold Change and 90% CI" showing comparisons of AUC and Cmax values. The x-axis represents change relative to reference from 0.5 to 3.0, and the y-axis lists special populations such as CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and renal impairment. Data points with error bars illustrate fold changes for each category.*
FDA Label Image

Aripiprazolefigure5 (Aripiprazolefigure5)

Aripiprazolefigure5 (Aripiprazolefigure5)
A pharmacokinetic chart titled "Dehydro-Aripiprazole Fold Change and 90% CI" showing fold change in AUC and Cmax relative to reference for various factors including CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. Each factor's fold change is plotted with error bars depicting 90% confidence intervals.*
FDA Label Image

Aripiprazolefigure6 (Aripiprazolefigure6)

Aripiprazolefigure6 (Aripiprazolefigure6)
A line graph comparing the proportion of subjects with relapse over time from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis represents the proportion with relapse. The graph includes numbers of subjects at risk below the x-axis for both groups at multiple time points.*
FDA Label Image

Aripiprazolefigure7 (Aripiprazolefigure7)

Aripiprazolefigure7 (Aripiprazolefigure7)
A Kaplan-Meier plot showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole versus placebo. The graph includes the number of subjects at risk at various time points along the x-axis. Aripiprazole is represented by a solid line and placebo by a dashed line.*
FDA Label Image

Aripiprazolefigure8 (Aripiprazolefigure8)

Aripiprazolefigure8 (Aripiprazolefigure8)
A line graph comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes a risk table indicating the number of subjects remaining at various time points for each group.*
FDA Label Image

Aripiprazolefigure9 (Aripiprazolefigure9)

Aripiprazolefigure9 (Aripiprazolefigure9)
A line graph depicting the change in YGTSS Total TIC Score from baseline over 8 weeks of treatment. The graph compares three groups labeled: Abilify Low, Abilify High, and Placebo, showing a decrease in scores with Abilify treatments compared to Placebo over time.*
FDA Label Image

Aripiprazole2mg30s (Aripiprazole2mg30s)

Aripiprazole2mg30s (Aripiprazole2mg30s)
Label for Aripiprazole Tablets, USP 2 mg oral tablets by NorthStar Rx LLC. The label indicates 30 tablets per container with a note to dispense a medication guide separately. It includes storage instructions and manufacturing details by Hetero Labs Limited in India, with a barcode and batch coding area.*
FDA Label Image

Aripiprazole5mg30s (Aripiprazole5mg30s)

Aripiprazole5mg30s (Aripiprazole5mg30s)
Aripiprazole Tablets, USP 5 mg oral tablets, packaged in a bottle of 30 tablets. The label includes dosage instructions, storage conditions, and dispensing information. Manufactured for NorthStar Rx LLC and by Hetero Labs Limited in India. Barcode and batch coding area are also visible.*
FDA Label Image

Aripiprazole10mg30s (Aripiprazole10mg30s)

Aripiprazole10mg30s (Aripiprazole10mg30s)
Label for Aripiprazole Tablets, USP 10 mg oral tablets, packaged as 30 tablets. The label includes the NDC 16714-143-01, prescribing information advisory, storage instructions at 20° to 25°C, and manufacturer details for NorthStar Rx LLC, Memphis, Tennessee, with production by Hetero Labs Limited in India. Batch coding area and barcode are also visible.*
FDA Label Image

Aripiprazole15mg30s (Aripiprazole15mg30s)

Aripiprazole15mg30s (Aripiprazole15mg30s)
Aripiprazole Tablets, USP 15 mg oral tablets label. The label indicates a 30 tablet count and is manufactured by NorthStar Rx LLC. It includes dosage guidance referencing the Prescribing Information and storage instructions at controlled room temperature. The label also provides a Medication Guide availability statement and manufacturing details by Hetero Labs Limited, India.*
FDA Label Image

Aripiprazole20mg30s (Aripiprazole20mg30s)

Aripiprazole20mg30s (Aripiprazole20mg30s)
Label for Aripiprazole Tablets USP 20 mg, oral tablets, packaged in a container of 30 tablets. The label includes dosage information, storage instructions, manufacturer NorthStar RxLLC, and distributor Hetero Labs Limited in India. It also features a barcode, batch coding area, and a note about the Medication Guide availability.*
FDA Label Image

Aripiprazole30mg30s (Aripiprazole30mg30s)

Aripiprazole30mg30s (Aripiprazole30mg30s)
Aripiprazole Tablets, USP 30 mg oral tablets packaging label from NorthStar RxLLC. The label indicates a package size of 30 tablets with prescription only status. It includes storage instructions, a barcode, and manufacturer details stating the product is manufactured for NorthStar Rx LLC and by Hetero Labs Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.